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EDITORIAL COMMENT
The increased use of cross-sectional imaging has led to signiﬁcant stage migration in renal cell carcinoma (RCC). As more
computed tomography (CT) and magnetic resonance imaging
scans are performed for unrelated conditions, more RCCs have
been detected − particularly small, asymptomatic lesions. For
larger RCCs, obtaining chest imaging to rule out synchronous
lung metastasis (sLM) remains an important clinical principle,
supported by current guidelines. However, regarding chest imaging, guidelines do not necessarily reﬂect the stage migration in
RCC over the past decade.1 As smaller, more indolent, RCCs
are detected the optimal role of chest imaging with initial RCC
diagnosis remains unclear.
The authors of this well-presented manuscript investigated
the rate of sLM in RCC, stratifying patients by tumor size. While
prior studies have demonstrated a correlation between increasing
tumor size and synchronous metastasis, the strength and slope of
this relationship remain unclear in contemporary patients. By
examining this statistical relationship, clinicians may better
understand sLM rates for a newly diagnosed RCC and offer chest
imaging when most appropriate.
The authors utilized the National Cancer Database, evaluating 253,838 patients with RCC between 2010 and 2016. Of
these patients, 5.7% (14,524) had a sLM. Patients were stratiﬁed
by RCC size and the rate of sLM was calculated at 10-millimeter
(mm) intervals. For tumors under 40 mm, only 0.9% had an
sLM. Conversely, for tumors 90 mm and above, the sLM rate
was roughly 20%. Figure 1 illustrates this graphically as the sLM
versus RCC size plot produces a linear-quadratic function. Multivariable logistic regression also demonstrated that RCC size
remained an important predictor of sLM, particularly for those
greater than 40 mm (Table 2).
The above study offers important insights regarding the incidence of sLMs in patients with newly diagnosed RCC. Of note,
approximately 8% (1,135/14,525) of patients with a sLM had a
RCC <40 mm. Avoiding low-yield imaging for lower risk lesions
could inﬂuence healthcare costs, radiation exposure, and patient
counseling.2 However, the treatment paradigms for patients with
metastatic RCC differ vastly from those for localized disease,
including the clinical trial options available.3 Patients with

oligometastatic disease often require systemic therapy, cytoreductive nephrectomy, and/or metastasectomy.4 While sLMs in
cT1a RCC are rare, missing these cases may have a profound
effect on treatment decisions and survival outcomes. Thus,
implementing a risk-adapted chest imaging protocol requires
careful patient counseling. One must not only incorporate rates
of sLM into the discussion, but also the impact of not capturing
sLM at the time of diagnosis, and its potential implications for
survival.

Arnav Srivastava, Brian Shinder, Eric A. Singer,
Rutgers Cancer Institute of New Jersey, Section of Urologic
Oncology
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AUTHOR REPLY
We thank Dr. Singer and colleagues for their thoughtful comments on our investigation of synchronous lung metastasis
(sLM) in patients with newly identiﬁed renal masses (RMs). As
stated in our original investigation and by the editors, we
assessed a large cohort of 253,818 patients. Of these patients,
120,386 (47%) had a RM size <40 mm. Furthermore, only 0.9%
of patients with a RM size <40 mm displayed sLM. When examining only patients with conﬁrmed sLM we found that only 8%
(1,135/14,524) had a RM <40 mm.
It is paramount to consider the malignant and metastatic
potential of small renal masses (SRM) when interpreting our
data. Previous investigations have shown that 20%-40% of
SRMs are in fact benign.1 All RMs in our investigation had histopathological conﬁrmation of malignancy, therefore, our results
likely over inﬂated the true metastatic potential of SRMs one
would identify in the general population, again putting into
question the true utility of staging chest imaging for RM
<40 mm. It is also noteworthy that the presence of positive chest
imaging does not automatically conclude the presence of metastatic disease. Interestingly, examining a population of patients
with SRMs managed with surveillance, Kassiri et al reported
that among patients with lung ﬁndings which were deemed
actionable, 0% were found to be metastatic lesions.2 This further
highlights that the radiative, emotional, and cost burden of
potentially unnecessary workup may not always halt with initial
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chest screening but can be prolonged in pursuit of ultimately
negative diagnostic tests and procedures.
Lastly, the author’s agree with the editor’s comment regarding
the potentially devastating effect of missing sLM. That said, cutoffs in medicine are generally based on a delicate balance of beneﬁt versus cost. For example, it has been shown that a small percentage of patients with a PSA < 4.00 ng/mL harbor high-risk
prostate cancer, yet contemporary guidelines recommendation
against biopsy in these individuals because of the very limited
beneﬁt and yield.3,4 Ultimately, the authors emphasize the
importance of a shared and well-informed decision between a
patient and provider in the initial staging of SRMs.
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